Alzheimer’s Disease – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report both the incidence and prevalence of AD for each country and the number of drug-treatment opportunities in each market.
DRG Epidemiology’s AD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with AD per year?
- How will improvements in survival change the number of people living with a diagnosis of AD?
- Of all people with AD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with AD, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we depict the patient flow between or within different disease states for the United States, Europe, and Japan. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following AD subpopulations:
- Twenty-year total prevalent cases of asymptomatic AD.
- Twenty-year total prevalent cases of MCI due to AD by symptoms.
- Twenty-year total prevalent cases of symptomatic MCI due to AD by diagnosis status.
- Total prevalent cases of AD.
- Total prevalent cases of AD by severity (mild, moderate, severe).
- Total prevalent cases of AD by diagnosis status.
- Diagnosed prevalent cases of AD by symptom status (agitation, depression, hallucinations).
- Diagnosed prevalent cases of MCI due to AD by drug-treatment status
- Diagnosed prevalent cases of AD by drug-treatment status.
- Diagnosed prevalent cases of mild AD by drug-treatment status.
- Diagnosed prevalent cases of moderate AD by drug-treatment status.
- Diagnosed prevalent cases of severe AD by drug-treatment status.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Alzheimer's Disease - Epidemiology - Mature Markets
- Introduction
- Total Prevalence of Alzheimer's Disease per 1,000 People Aged 30+ in 2020 and 2040
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease over the Next 20 Years
- Analysis of Total Prevalent Cases of Alzheimer's Disease by Diagnosed and Drug-Treated Status
- Analysis of Total Prevalent Cases of Alzheimer's Disease in 2020 by Severity
- Number of Additional Total Prevalent Cases of Alzheimer's Disease Incurred over 2020-2040 in the Countries Under Study
- Epidemiology Data
- Methods
- 2020 Model Update
- Total Asymptomatic Alzheimer's Disease Incident Cases
- Multistate Model of the Progression of Alzheimer's Disease
- Total Mild Cognitive Impairment due to Alzheimer's Disease Incident Cases
- Total Alzheimer's Disease Incident Cases
- Total Asymptomatic Alzheimer's Disease Prevalent Cases
- Total Mild Cognitive Impairment Due to Alzheimer's Disease Prevalent Cases
- Total Alzheimer's Disease Prevalent Cases
- Total Alzheimer's Disease by APOE e4 Status Prevalent Cases
- Diagnosed MCI due to AD and Alzheimer's Disease Prevalent Cases
- Diagnosed Alzheimer's Disease by Severity Prevalent Cases
- Diagnosed Alzheimer's Disease by Symptom Status Prevalent Cases
- Diagnosed Drug-Treated Alzheimer's Disease by Severity Prevalent Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Alzheimer's Disease
- Studies Excluded from the Analysis of Alzheimer's Disease
- Risk/Protective Factors
- Risk/Protective Factors for Alzheimer's Disease
- Bibliography
- Glossary
- Literature Review
- Introduction
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.